Raiffeisen-HealthCare-Részvény Alap (R)

Fund Management Report

Health care shares moved sideways again in October. The reporting season kicked off, with mixed results to date. The upcoming US election caused elevated uncertainty. Health care shares came back into the spotlight because of the increasing number of COVID cases. Abbott Laboratories delivered good results in the diagnostics segment. Gilead obtained FDA approval for Remdesivir. BioNTech and Thermo Fisher generated positive contributions for the fund. Shares in M3, Zur Rose, Intercept, and Livanova were sold during the period while new positions were set up in Agilent and Fisher & Paykel. The positions in Merck, Amgen, BioNTech, and Glaxo were increased. The increased research spending in the context of COVID-19 will support broad sections of the health care sector. (23.10.2020)